Forty Seven (Forty Seven) Beneish M-Score : 0.00 (As of May. 22, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Forty Seven Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Forty Seven's Beneish M-Score or its related term are showing as below:

During the past 4 years, the highest Beneish M-Score of Forty Seven was 0.00. The lowest was 0.00. And the median was 0.00.

Forty Seven Beneish M-Score Historical Data

The historical data trend for Forty Seven's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forty Seven Beneish M-Score Chart

Forty Seven Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Beneish M-Score

Forty Seven Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
Beneish M-Score	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Forty Seven's Beneish M-Score

For the Biotechnology subindustry, Forty Seven's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forty Seven's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forty Seven's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Forty Seven's Beneish M-Score falls into.

Forty Seven Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Forty Seven for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Dec19) TTM:

Last Year (Dec18) TTM:

Total Receivables was $0.00 Mil.
Revenue was 0 + 15.678 + 0 + 0 = $15.68 Mil.
Gross Profit was 0 + 15.678 + 0 + 0 = $15.68 Mil.
Total Current Assets was $337.52 Mil.
Total Assets was $343.59 Mil.
Property, Plant and Equipment(Net PPE) was $3.20 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.59 Mil.
Selling, General, & Admin. Expense(SGA) was $20.42 Mil.
Total Current Liabilities was $22.80 Mil.
Long-Term Debt & Capital Lease Obligation was $0.84 Mil.
Net Income was -26.236 + -15.163 + -23.206 + -23.016 = $-87.62 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -22.258 + -13.186 + -15.366 + -27.303 = $-78.11 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $145.86 Mil.
Total Assets was $149.44 Mil.
Property, Plant and Equipment(Net PPE) was $1.36 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.40 Mil.
Selling, General, & Admin. Expense(SGA) was $15.43 Mil.
Total Current Liabilities was $15.41 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0 / 15.678)	/	(0 / 0)
	=	0	/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(15.678 / 15.678)
	=		/	1
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (337.524 + 3.201) / 343.593)	/	(1 - (145.858 + 1.36) / 149.437)
	=	0.008347	/	0.014849
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	15.678	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.401 / (0.401 + 1.36))	/	(1.586 / (1.586 + 3.201))
	=	0.227712	/	0.331314
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(20.418 / 15.678)	/	(15.432 / 0)
	=	1.302334	/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.844 + 22.795) / 343.593)	/	((0 + 15.409) / 149.437)
	=	0.068799	/	0.103114
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-87.621 - 0	-	-78.113)	/	343.593
	=	-0.027672

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Forty Seven Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Forty Seven's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Forty Seven (Forty Seven) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

1490 Oâ€™Brien Drive, Suite A, Menlo Park, CA, USA, 94025

Website

https://www.fortyseveninc.com

Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.

Executives

Dennis Henner	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball	director	C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads	officer: Chief Financial Officer	4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird	director	755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c.	10 percent owner	C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154